Illumina this week named Charles Dadswell as senior vice president and general counsel.
Dadswell takes over for Christian Cabou, who has retired. He will have worldwide responsibility for all legal and IP matters, and will serve as secretary to Illumina's board of directors.
Dadswell joins Illumina from BioMérieux, where he was most recently vice president, general counsel for North and Latin America and corporate director of global intellectual property.
Prior to BioMérieux, he was general counsel of BioDelivery Sciences International; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome, and GlaxoSmithKline.
Applied BioCode said this week that Michael Aye is the company's new vice president of molecular products.
Aye has more than eight years of research and development experience at companies such as Focus Diagnostics (a division of Quest Diagnostics) and Beckman Coulter. Prior to his industrial experience Aye spent 10 years in academia focused on research in molecular genetics and microbiology.
Cepheid disclosed during its first-quarter earnings call last week that Warren Kocmond will join the company on May 6 as executive vice president of global operations.
Kocmond is currently vice president of global operations for Lam Research, and has previously served as executive vice president of memory products at Verigy; CEO of Electroglas; and senior vice president of global operations at Affymetrix.